Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Tooth-Saving materials put to the test against standard treatment

NCT ID NCT07660549

Disease control Sponsor: Cukurova University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three different materials used to treat severe, irreversible tooth inflammation. 72 adults with painful molars received a procedure where the damaged pulp was removed and covered with one of the materials. The goal was to see if newer materials (TheraCal LC and TheraCal PT) work as well as the standard material (MTA) for controlling pain and saving the tooth over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mineral trioxide aggregate, TheraCal LC, and TheraCal PT (dental pulp capping materials)
What this could lead to
If successful, this could show that newer, easier-to-use materials work as well as the standard material for saving teeth with severe pulp inflammation.
What could go wrong
This is a small, completed trial with only 72 participants, so results may not apply to all patients. The materials are already in use, so no major new breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Dec 2024

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients requiring full pulpotomy treatment in mandibular first or second permanent molars diagnosed with symptomatic irreversible pulpitis. * Mandibular first or second permanent molars with a preoperative Visual Analogue Scale (VAS) pain score ≥4, indicating moderate or severe pain. * Vital mandibular first or second permanent molars showing positive responses to both cold and electric pulp tests. * Teeth with deep carious lesions indicated for vital pulp therapy. * Teeth with no radiographic evidence of periapical pathology. * Patients who had not taken analgesics or antibiotics within the 24 hours preceding the procedure. Exclusion Criteria: * Non-vital mandibular permanent molars showing negative responses to cold or electric pulp tests. * Non-restorable teeth. * Teeth with root caries, open apex, pulp calcification, internal or external resorption, or periodontal involvement. * Mandibular first or second permanent molars with poor periodontal status, defined as periodontal pocket depth \>4 mm. * Teeth with radiographic evidence of periapical pathology. * Patients with systemic conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, chronic kidney disease, hematological disorders, or a history of chemotherapy or radiotherapy. * Patients with contraindications to full pulpotomy treatment or local anesthesia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulpitis - irreversible are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulpitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulpitis - irreversible

Contacts and locations

Locations

  • Cukurova University

    Adana, Sarıçam, 01250, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.